AUPH Q1 2025 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$62M+24.2% YoY

Gross Profit

$54M86.3% margin

Operating Income

$22M35.0% margin

Net Income

$23M37.4% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

$1M

Stock-Based Comp.

-$3M

Balance Sheet

Total Assets

$505M

Total Liabilities

$155M

Stockholders' Equity

$350M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$62M	$50M	+24.2%
Gross Profit	$54M	$43M	+26.7%
Operating Income	$22M	-$11M	+304.3%
Net Income	$23M	-$11M	+317.2%

Revenue Segments

Product

$60M96%

License, Collaboration and Royalty Revenue

$2M4%